CAS: 1352610-25-3
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | Vactosertib Hydrochloride REF: IN-DA01EO6KCAS: 1352610-25-3 | 98% | To inquire | Tue 07 Jan 25 |
 | Vactosertib Hydrochloride REF: TM-T15262CAS: 1352610-25-3 | 98% | 52.00 €~99.00 € | Tue 14 Jan 25 |
 | Vactosertib Hydrochloride REF: 3D-CEC61025CAS: 1352610-25-3 | Min. 95% | To inquire | Tue 18 Feb 25 |
Ref: IN-DA01EO6K
| 25mg | 186.00 € | ||
| 50mg | 225.00 € | ||
| 100mg | 507.00 € |
Estimated delivery in United States, on Tuesday 7 Jan 2025
Vactosertib Hydrochloride
CAS:1352610-25-3
Vactosertib HCl: oral ATP-competitive ALK5 inhibitor, IC50=12.9 nM; anticancer, antimetastatic, also targets ALK2/4.
Formula:
C22H19ClFN7
Purity:
98%
Color and Shape:
Solid
Molecular weight:
435.89
Ref: TM-T15262
| 2mg | 84.00 € | ||
| 5mg | 99.00 € |
Estimated delivery in United States, on Tuesday 14 Jan 2025
Vactosertib Hydrochloride
CAS:1352610-25-3
Vactosertib hydrochloride is a small molecule that binds to the receptor tyrosine kinase AXL and …
Formula:
C22H19ClFN7
Purity:
Min. 95%
Molecular weight:
435.88 g/mol
Ref: 3D-CEC61025
| 1mg | To inquire | ||
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Tuesday 18 Feb 2025
